D-0661-2026 Class II Ongoing

Recalled by Cipla USA, Inc. — Warren, NJ

FDA drug recall D-0661-2026 was initiated by Cipla USA, Inc. on Jun 29, 2026 and is designated Class II. Reason for recall: cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). The recall status is ongoing. Affected quantity: 31,824 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 8, 2026
Initiation Date
Jun 29, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
31,824 bottles

Product description

Cinacalcet Hydrochloride Tablets, 30 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-410-02

Reason for recall

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

Distribution pattern

USA Nationwide

Code information

Lot #: 5PB0465, 5PB0466, 5PB0557, Exp 4/30/2027; 5PB0629, 5PB0630, 5PB0633, 5PB0637, 5PB0638, Exp 6/30/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0661-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0661-2026. Report a data issue: hello@regdatalab.com.